Embody vs MyStart Health
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Embody
Best for lowest first-month entry pricing on compounded GLP-1sStarting at $99/mo
MyStart Health
Best for fastest compounded GLP-1 onboarding with a price lockStarting at $299/mo
Side-by-Side Comparison
| Feature | Embody | MyStart Health |
|---|---|---|
| Overall Score | ✓8.5/10 | 7.7/10 |
| Starting Price | ✓$99/mo | $299/mo |
| Editorial Rating | ✓4.3 ★ /5 | 3.9 ★ /5 |
| Features | 6 features | 6 features |
| States Available | 0 | 0 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Embody
Pros
- ✓Lowest first-month entry pricing in the compounded segment ($99 first month for semaglutide, $149 for tirzepatide injection)
- ✓Unique compounded oral tirzepatide gum formulation — alternative for patients who prefer not to inject
- ✓Available in all 50 states with no insurance friction
- ✓24/7 unlimited clinician messaging and dose-adjustment support included
- ✓Medical leadership by Dr. Alan Viglione, board-certified in Internal Medicine
Cons
- ✗Refill pricing jumps to $299/month after the first month — initial $99/$149 is an intro rate, not the ongoing cost
- ✗Compounded only — no FDA-approved brand-name Ozempic, Wegovy, Zepbound, or Mounjaro option
- ✗Pharmacy partners not publicly named — compounding source transparency is limited
- ✗Compounded oral tirzepatide does not have an FDA-approved counterpart, and oral GLP-1 bioavailability remains an active area of clinical debate
MyStart Health
Pros
- ✓Price Lock Guarantee — base monthly rate ($299) doesn't increase even when your prescribed dose escalates
- ✓Fast onboarding: quoted 5-minute intake, 24-hour prescription turnaround, 2–4 day shipping
- ✓24/7 access to the care team with unlimited clinician messaging included
- ✓LegitScript certified
- ✓Transparent Section 503A compounding disclosure on every landing page
Cons
- ✗Not BBB accredited — BBB rating of C+ with 10 complaints filed against the business (BBB file opened April 24, 2025), most involving shipping delays and customer service access issues in early 2026
- ✗Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro
- ✗Oral tirzepatide referenced in marketing but FAQ clarifies injectable is 'currently more common' — no FDA-approved oral tirzepatide exists, and the November 2025 Chimicles class action against OpenLoop/Triad Rx over unapproved oral tirzepatide products is a cautionary data point for the category
- ✗Very recent company (incorporated May 21, 2024 per BBB) — limited operational track record
- ✗Pharmacy partners not publicly named — no independent way to verify 503A compliance
- ✗Clinical efficacy claims are based on a homepage survey of only 16 self-reporting customers
Our Verdict
Embody edges out MyStart Health with a higher overall score of 8.5/10 and is particularly strong for lowest first-month entry pricing on compounded GLP-1s. MyStart Health remains a solid alternative, especially if you're looking for fastest compounded GLP-1 onboarding with a price lock.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.